Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03873623
Other study ID # 16-003159
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 2016
Est. completion date December 19, 2019

Study information

Verified date February 2022
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Researchers are trying to develop a way to customize immunosuppression treatment, based on the results of a blood test that measures the risk of rejection.


Recruitment information / eligibility

Status Completed
Enrollment 250
Est. completion date December 19, 2019
Est. primary completion date December 19, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Conventional solitary kidney transplant (ABO compatible, crossmatch negative, not a kidney transplant simultaneously transplanted with another non-renal organ including heart, liver, lung or pancreas) - Patients who have given informed consent and are willing to comply with the protocol, including the use of their specimens and data for subsequent research. Exclusion Criteria: - EBV -seronegative recipient - ABO incompatible kidney transplants. - Simultaneous kidney and extra-renal organ transplants including pancreas, liver, heart, lung, bone marrow transplantation, etc or prior recipient of non-renal transplant. Subjects who had previous extra renal transplants may be included in the study. - Positive crossmatch kidney transplants (T cell crossmatch >100, B flow cytometric crossmatch >150). - Participating in other clinical trials - Any kidney transplant recipient < 18 years of age.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Mayo Clinic Jacksonville Florida
United States Mayo Clinic Rochester Minnesota
United States Mayo Clinic Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To correlate the findings of TruGraf (a peripheral blood RNA signature that has been shown to correlate with rejection in renal allografts) with rejection episodes in renal transplant patients . The study will validate the ability of a peripheral blood assay to assess the risk of rejection and determine the role this assay will have in immunosuppression monitoring in our patients at Mayo Clinic (3 sites). 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04491552 - TruGraf® Long-term Clinical Outcomes Study
Withdrawn NCT04560582 - Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Completed NCT05747274 - SRDK0921_ Analytical Performance Study
Not yet recruiting NCT05482100 - CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
Recruiting NCT06243289 - Improving KIdney Transplantation With Cellular Therapy Study
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed NCT04367610 - Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Enrolling by invitation NCT06126380 - Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients Phase 2
Terminated NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Active, not recruiting NCT03714113 - Donor-specific Anti-HLA Antibodies Monitoring in Kidney Transplant Recipients N/A
Recruiting NCT04091984 - The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
Recruiting NCT05335538 - TruGraf and TRAC In Pediatrics Study
Completed NCT03663335 - Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients Phase 2
Completed NCT03652402 - Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN
Recruiting NCT04773392 - Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR Phase 4
Terminated NCT02974686 - Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation Phase 4
Terminated NCT04156204 - Immunosuppressant Medication Dosed Daily After Kidney Transplant Early Phase 1
Completed NCT04601155 - Transition of Renal Patients Using AlloSure Into Community Kidney Care
Completed NCT03874299 - The TOGETHER Project - Kidney RNA-seq Validation
Completed NCT03965559 - The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant

External Links